ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02107963 (A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors), which is not on this map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Who cites it
71 citing papers in PubMed, 128 citations in OpenAlex.
- Bone Marrow-derived CD8+ T Cells From Pediatric Leukemia Patients Express PD1 and Expand Ex Vivo Following Induction Chemotherapy.Journal of pediatric hematology/oncology · 2019Trial
- Neurotoxicity after CTL019 in a pediatric and young adult cohort.Annals of neurology · 2018Trial
- Preclinical evaluation of nitrated α-synuclein-specific CAR-Treg therapy in Parkinson's disease.Cell reports. Medicine · 2026Article
- Roles of inflammatory cytokines in the pathogenesis of hepatitis B virus-related acute-on-chronic liver failure and CAR-T therapy.Virology journal · 2025Article
- CAR-T cells for pediatric malignancies: Past, present, future and nursing implications.Asia-Pacific journal of oncology nursing · 2023Review
- Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro.Heliyon · 2023Article
- Computational Methods in Immunology and Vaccinology: Design and Development of Antibodies and Immunogens.Journal of chemical theory and computation · 2023Review
- Walking a Fine Germline: Synthesizing Public Opinion and Legal Precedent to Develop Policy Recommendations for Heritable Gene-Editing.Journal of bioethical inquiry · 2022Article
- Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model.Molecular therapy oncolytics · 2022Article
- Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.Frontiers in immunology · 2022Article
- Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview.Cancers · 2020Review
- Antitumor effects of targeting myeloid-derived suppressive cells.Translational cancer research · 2020Review
- Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach.Cancer immunology, immunotherapy : CII · 2020Article
- Magnetic Nanoparticles in Cancer Therapy and Diagnosis.Advanced healthcare materials · 2020Review
- Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.Current oncology reports · 2020Review
- An Engineered Tumor-on-a-Chip Device with Breast Cancer-Immune Cell Interactions for Assessing T-cell Recruitment.Cancer research · 2020Article
- Immunotherapeutic Challenges for Pediatric Cancers.Molecular therapy oncolytics · 2019Review
- Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.Journal of pediatric hematology/oncology · 2019Review
- Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy.Therapeutics and clinical risk management · 2019Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Improved outcomes for children with cancer hinge on the development of new targeted therapies with acceptable short-term and long-term toxicity. Progress in basic, preclinical, and clinical arenas spanning cellular immunology, gene therapy, and cell-processing technologies have paved the way for clinical applications of chimeric antigen receptor-based therapies. This is a new form of targeted immunotherapy that merges the exquisite targeting specificity of monoclonal antibodies with the potent cytotoxicity, potential for expansion, and long-term persistence provided by cytotoxic T cells. Although this field is still in its infancy, clinical trials have already shown clinically significant antitumor activity in neuroblastoma, chronic lymphocytic leukemia, and B-cell lymphoma, and trials targeting a variety of other adult and pediatric malignancies are under way. Ongoing work is focused on identifying optimal tumor targets and elucidating and manipulating both cell- and host-associated factors to support expansion and persistence of the genetically engineered cells in vivo. In pediatric oncology, CD19 and GD2 are compelling antigens that have already been identified for targeting pre-B acute lymphoblastic leukemia and neuroblastoma, respectively, with this approach, but it is likely that other antigens expressed in a variety of childhood cancers will also soon be targeted using this therapy. The potential to target essentially any tumor-associated cell-surface antigen for which a monoclonal antibody can be made opens up an entirely new arena for targeted therapy of childhood cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.